

**FOR PCT
NATIONAL PHASE
ORIGINAL
DECLARATION**

**RULE 63 (37 C.F.R. 1.63)
DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled **RECOMBINANT POLYPEPTIDES OF THE MEMBERS OF THE TNF LIGAND FAMILY AND USE THEREOF**, the specification of which was filed as U.S. Application Serial No. 10/594,169 on September 25, 2006.

I further declare that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. Except as noted below, hereby waive any foreign priority benefits under 35 U.S.C. 119(a)(d) or 365(b) of any foreign application(s) for patent or Inventor's certificate, or 365(a) of any PCT International Application which designated at least one other country than the United States, listed below and not also recited below any foreign application for patent or Inventor's certificate, or PCT International Application, filed by me or my assignee disclosing the same subject matter claimed in this application and having a filing date (1) before that of the application on which priority is claimed, or (2) if no priority claimed, before the filing date of this application.

PRIOR FOREIGN APPLICATION(S)

Number	Country	Filed	Date First Laid Open Or Published	Date Patented or Granted	Priority Claimed
10 2004 014 983.6	DE	March 26, 2004			Yes

Except as noted below, I hereby claim domestic priority benefit under 35 U.S.C. 119(e) or 120 and/or 365(c) of the indicated United States applications listed below and PCT International applications listed above or below and, if this is a continuation-in-part (CIP) application, Insofar as the subject matter disclosed and claimed in this application is in addition to that disclosed in such prior applications, I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56 which became available between the filing date of each such prior application and the national or PCT International filing date of this application:

PRIOR U.S. PROVISIONAL, NONPROVISIONAL AND/OR PCT APPLICATION(S)

Application Number	Filed	Status	Priority Claimed
PCT/EP2005/003156	March 24, 2005	pending, abandoned, patented	Yes

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

And I hereby appoint Pillsbury Winthrop Shaw Pittman LLP, Intellectual Property Group, (to whom all communications are to be directed), and persons of that firm who are associated with USPTO Customer Relationship Management system, to prosecute this application and to handle all business in the Patent and Trademark Office on behalf of my assignee and the resulting patent, and I hereby authorize them to delete from that Customer No. names of persons no longer with their firm, to advise persons of their firm to that Customer No., and to act and rely on instructions from and communicate directly with the person/designee/attorney/firm/organization who/which first sends/ent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct the above Firm and/or an attorney of that Firm in writing to the contrary.

Power of Attorney to Customer Number

27500


and the successors, assigns and legal representatives of the ASSIGNEE the entire right, title and interest for the United States and its territorial possessions and in all foreign countries, including all rights to claim priority, in and to any and all improvements which are disclosed in the invention entitled:

RECOMBINANT POLYPEPTIDES OF THE MEMBERS OF THE TNF LIGAND FAMILY AND USE THEREOF

and which is found in (37 C.F.R. § 3.21) U.S. application no. 10/594,189 filed on September 25, 2006 and any legal equivalent thereof in a foreign country, including the right to claim priority and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, renewal, or substitute thereof, and as to letters patent any reissue or re-examination thereof.


ASSIGNORS hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

ASSIGNORS further covenant that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNORS and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.




Signature of Klaus Pfeumaier

Date: 09-07-2007




Signature of Peter Scheurich

Date: 09-07-2007



Signature of Ilse Grunwald

Date: 28-06-07



Signature of Anja Krippner-Heidenreich

Date: 07/03/2007